Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Cellular Biomarkers Correlate with Disease Severity in Sjögren Disease

By LabMedica International staff writers
Posted on 26 Jun 2026

Autoimmune disorders arise when immune responses target self-antigens, driving chronic inflammation and long-term morbidity. More...

In primary Sjögren disease, inflammation of salivary and lacrimal glands leads to dry mouth and dry eyes alongside systemic complications, underscoring an unmet need for disease-modifying strategies. CD4+ T cells are key orchestrators, but contributions from tissue-resident cells remain poorly defined. A new study reveals a disease-driving interaction between immune cells and fibroblasts in primary Sjögren disease.

Researchers at Tokushima University (Tokushima, Japan) describe a pathogenic axis between CD153+ CD4+ T cells and CD30+ fibroblasts in primary Sjögren disease (pSjD). The work identifies nonimmune fibroblasts, the structural cells that form tissue architecture, as active contributors to disease propagation rather than passive bystanders. The authors present this immune–stromal crosstalk as a central driver of glandular inflammation.

Using a mouse model of pSjD, the team performed high-resolution single-cell RNA sequencing and T cell receptor sequencing of salivary gland cells to map cellular interactions. The analysis showed that CD153+ CD4+ T cells directly engage CD30+ fibroblasts, triggering fibroblast activation, proliferation, and secretion of inflammatory chemokines. These signals recruit additional immune cells and sustain tertiary lymphoid structure–like tissues within the glands, creating a self-reinforcing pathogenic microenvironment.

Functional experiments further supported the role of this pathway. Removing CD153 from CD4+ T cells or neutralizing fibroblast-derived chemokines reduced immune-cell infiltration and significantly halted autoimmune-like pathology in the mouse model. Analyses of patient samples similarly showed increased CD153+ CD4+ T cells and CD30+ fibroblasts that preferentially interact, with CD153–CD30 axis activity positively correlating with disease severity. The expansion of these cells in affected tissues may therefore serve as a novel biomarker for diagnosis and/or monitoring of disease progression.

The findings were published in Nature Communications. Participating institutions include the Department of Immunology and Parasitology, Graduate School of Medicine, Tokushima University, and the Department of Oral and Maxillofacial Surgery, Tokushima University Hospital. 

“Our study provides a new perspective on autoimmune diseases and demonstrates that chronic inflammation is maintained not only by abnormal immune cells but also through interactions between immune cells and tissue-resident fibroblasts,” said Kunihiro Otsuka, Assistant Professor, Department of Oral and Maxillofacial Surgery, Tokushima University Hospital, Japan.

“Importantly, it highlights that fibroblasts create a pathological microenvironment that worsens the diseased condition through direct interaction with abnormal immune cells. This concept has significant implications in therapeutics for rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and chronic inflammatory disorders associated with fibrosis,” added Otsuka.

Related Links
Tokushima University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.